Viridian Therapeutics, Inc. (0K1R.L) LSE

32.50

-0.245(-0.75%)

Updated at December 24 02:32PM

Currency In USD

Valuation

Market Cap1.3B
Enterprise Value1.22B
P/E Ratio-7.66
PEG Ratio-14.74
Price/Sales Ratio8,591.78
Price/Book Ratio5.11
Enterprise/Revenue8,277.08
Enterprise/EBITDA-7.41

Fiscal Year

Fiscal YearDecember 31, 2024
Most Recent QuarterSeptember 30, 2025

Profitability

Profit Margin-1,128.07
Operating Margin-1,218.31

Management Effectiveness

Return On Assets-0.59
Return On Equity-0.55

Income Statement

Revenue302,000
Revenue/Share0
Gross Profit302,000
EBITDA-265.66M
Net Income-269.95M
Diluted EPS-3.98

Balance Sheet

Total Cash490.9M
Total Cash/Share6.9
Total Debt23.82M
Total Debt/Equity0.04
Current Ratio11.01
Book Value Per Share6.31

Price History

52-Week Change69.01
52-Week High32.5
52-Week Low10.98
Moving Average 50 Days20.02
Moving Average 200 Days19.53

Statistics

Average Volume682
Shares Outstanding81.18M
% Held by InstitutionsN/A

Dividend And Splits

Trailing Annual Dividend Rate0
Trailing Annual Dividend Yield0
Payout Ratio0
Last Split Factor1:15
Last Split DateSeptember 21, 2021